InflaRx NV (IFRX)
2.21
+0.05
(+2.31%)
USD |
NASDAQ |
Sep 02, 11:50
InflaRx Cash from Operations (Annual) : -39.86M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -39.86M |
| December 31, 2024 | -52.52M |
| December 31, 2023 | -40.88M |
| December 31, 2022 | -35.46M |
| December 31, 2021 | -47.20M |
| December 31, 2020 | -41.64M |
| Date | Value |
|---|---|
| December 31, 2019 | -48.36M |
| December 31, 2018 | -27.97M |
| December 31, 2017 | -13.71M |
| December 31, 2016 | -5.523M |
| December 31, 2015 | -3.668M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| MediGene AG | -- |
| BioNTech SE | 514.63M |
| Immatics NV | -199.34M |
| Beam Therapeutics, Inc. | -345.10M |
| Kymera Therapeutics, Inc. | -232.89M |